FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354: II. Anti-hyperglycemic effects in diabetic animal models

Journal of Antibiotics

Volumn 58, Issue 8, 2005, Pages 503-506

  Furukawa, Shigetada ^a   Murakami, Kana ^a   Nishikawa, Motoaki ^a   Nakayama, Osamu ^a   Hino, Motohiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Fungal metabolite; Glycogen phosphorylase inhibitor; Hypoglycemic effect

Indexed keywords

ANTIDIABETIC AGENT; FR 258900; GLUCAGON; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ISOLATION; DRUG MECHANISM; EXPERIMENTAL MODEL; FUNGAL STRAIN; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HYPERGLYCEMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALIA; FUNGI;

EID: 25144503390     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2005.67     Document Type: Article

References (9)

1. Furukawa S, Tsurumi Y, Murakami K, Nakanishi T, Ohsumi K, Hashimoto M, Nishikawa M, Takase S, Nakayama O, Hino M. FR258900, a novel glycogen phosphorylase inhibitor isolated from fungus No. 138354. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot 58: 497-502 (2005)
2. Treadway JL, Mendys P, Hoover DJ. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Exp Opin Invest Drugs 10: 439-454 (2001)
3. Ohtsu Y, Sasamura H, Shibata T, Nakajima H, Hino M, Fujii T. The novel gluconeogenesis inhibitor FR225659 and related compounds that originate from Helicomyces sp. No. 19353. II. Biological profiles. J Antibiot 56: 689-693 (2003)
4. Gómez-Lechón MJ, Ponsoda X, Castell JY A microassay for measuring glycogen in 96-well-cultured cells. Anal Biochem 236: 296-301 (1996)
5. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 15: 430-441 (1992)
6. Barrett EJ, Liu Z. Hepatic glucose metabolism and insulin resistance in NIDDM and obesity. Baillieres Clin Endocrinol Metab 7: 875-901 (1993)
7. Diraison F, Large V, Brunengraber H, Beylot M. Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM. Diabetologia 41: 212-220 (1998)
8. Hellerstein MK, Neese RA, Linfoot P, Christiansen M, Turner S, Letscher A. Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study. J Clin Invest 100: 1305-1319 (1997)
9. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA 95: 1776-1781 (1998)